G-LOW Combo (GH Optimised Fat Loss)
GH-axis targeted fat loss stack combining tesamorelin and ipamorelin for visceral fat reduction with AOD 9604 for direct adipose lipolysis. Based on the
Buy more, save more
Total Price
$230
For research & laboratory use only. Not for human consumption.
Half-Life
Varies by component
Administration Route
Subcutaneous injection
Effect Profile
Combined Efficacy
Synergistic Action
Protocol Coverage
Value
Mechanism of Action
Product FAQs
Stacks Well With
Tesamorelin
FDA-approved GHRH analogue (Egrifta) for HIV-associated visceral fat reduction. The most clinically validated GHRH peptide for abdominal fat mobilisation and
Ipamorelin
Highly selective growth hormone secretagogue with minimal cortisol or prolactin stimulation, offering clean GH pulses for muscle growth, recovery, and body
AOD 9604
Modified fragment of human growth hormone (hGH 177-191) with selective lipolytic activity and no reported effect on blood glucose or IGF-1. Studied for adipose
Related Products
Tesamorelin
FDA-approved GHRH analogue (Egrifta) for HIV-associated visceral fat reduction. The most clinically validated GHRH peptide for abdominal fat mobilisation and
Ipamorelin
Highly selective growth hormone secretagogue with minimal cortisol or prolactin stimulation, offering clean GH pulses for muscle growth, recovery, and body
AOD 9604
Modified fragment of human growth hormone (hGH 177-191) with selective lipolytic activity and no reported effect on blood glucose or IGF-1. Studied for adipose
HGH Fragment 176-191
C-terminal fragment of human growth hormone (amino acids 176-191) with potent lipolytic activity. Studied for adipose reduction without the growth-promoting or